Table 1 Approved TCEs for cancer.
From: T cell engagers: expanding horizons in oncology and beyond
TCE (trade name) | Disease indication | Mechanism of action |
|---|---|---|
Blinatumomab (Blincyto) | Acute lymphocytic leukaemia (ALL) | Blinatumomab links T cells with CD19 receptors found on the surface of B cells. |
Glofitamab (Columvi) | Elapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL). | Glofitamab binds the CD3 receptor in T cells and links them to CD20 surface antigens found on B cells. |
Mosunetuzumab (Lunsumio) | Follicular lymphoma. | Mosunetuzumab binds the CD3 receptor in T cells and links them to CD20 surface antigens found on B cells. |
Tarlatamab (Imdelltra) | Small cell lung cancer (SCLC) | Binds to DLL3 on tumour cells and CD3 on T cells, tarlatamab enables the recruitment and activation of T cells. |
Tebentafusp (Kimmtrak) | Unresectable or metastatic uveal melanoma | Binds gp100 (a melanoma-associated antigen) through a high-affinity T cell receptor (TCR) binding domain and an anti-CD3 T-cell-engaging domain |
Elranatamab (Elrexfio™) | Multiple Myeloma (MM) | BCMA on MM and CD3 on T cells. |
Epcoritamab (Eplinky) | Diffuse large B-cell lymphoma | CD3xCD20 T cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. |
Teclistamab (Tecvayli) | Multiple Myeloma (MM) | Targeting both the CD3 receptor complex on T cells and BCMA on myeloma cells, teclistamab leads to T cell activation and subsequent lysis of BCMA+ cells. |
Talquetamab (Talvey) | Multiple Myeloma | It is a bispecific GPRC5D-directed CD3 T cell engager. |
